May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
New Chemotherapeutic Treatments for Retinoblastoma
Author Affiliations & Notes
  • N.A. Laurie
    Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN
  • M.A. Dyer
    Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN
  • Footnotes
    Commercial Relationships  N.A. Laurie, None; M.A. Dyer, None.
  • Footnotes
    Support  NIH, NSF, NCI, Pew Scholars, RPB
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3195. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N.A. Laurie, M.A. Dyer; New Chemotherapeutic Treatments for Retinoblastoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3195.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Retinoblastoma, the third most prevalent childhood cancer in children younger than 1 year, can be treated in its early stages with a combination of chemotherapy, laser therapy, and cryotherapy. In its late stages, however, this approach is not as effective.


We are currently testing new chemotherapeutic drugs and drug combinations for the purpose of discovering more effective treatments for retinoblastoma.


We have developed three new animal models that we are using to target these drugs. We are utilizing an orthotopic xenograft model, in which human retinoblastoma cells are injected into the eyes of newborn rats. We are also using an in vivo retroviral model, in which the replication–incompetent retrovirus (LIA–EE1A) encoding the E1A oncogene is injected into the eyes of newborn mice, which leads to the transformation of retinal progenitor cells into clonal focal tumors. Lastly, we have developed a genetic model, involving a conditional triple knock–out in the retina (Rblox/–, p107–/–, p53–/–, Chx10cre). In vitro, we have tested the effect of chemotherapeutic drugs on cell viability (live/dead assay), proliferation (BrdU), apoptosis (Tunel) (see picture), and cell cycle arrest (FACS). We have also tested the pharmacokinetics of these drugs in the vitreous, retina, and plasma of rats.


We have identified a novel drug combination that is more effective than the current standard triple therapy of etoposide, carboplatin, and vincristine.


Our animal models combined with cell culture and pharmacokinetics is an effective preclinical screen for new treatments.



Keywords: retinoblastoma • genetics • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.